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Background/aim: The aim of the study was to investigate the effects of whole blood viscosity and plasma nitric oxide on cerebral and
cardiovascular risks associated with chronic kidney disease.
Materials and methods: The study group consisted of 40 pediatric patients and 21 healthy control subjects. Hematologic and biochemical
variables, viscosity and plasma nitric oxide levels, echocardiographic findings, and middle cerebral artery blood flow velocity were
examined.
Results: Viscosity values of patients were significantly lower than those of the control group. Lower values of hematocrit, total protein,
and albumin and higher values of ferritin in all patient groups resulted in significantly low viscosity levels. Plasma nitric oxide levels
were higher in all patient groups than those in the controls. No statistically significant difference was present in middle cerebral artery
blood flow velocity between the patient and control groups. Even when systolic functions were normal, the patient group had significant
deterioration in diastolic functions, suggesting morbidity and mortality risks.
Conclusions: Cerebral blood flow velocities were not affected by viscosity and nitric oxide levels, suggesting that cerebral circulation
has the ability to make adaptive modulation. The metabolism of nitric oxide levels needs further investigation and studies in patients
with chronic renal disease.
Key words: Nitric oxide, viscosity, chronic renal failure, transcranial Doppler ultrasonography, echocardiography

1. Introduction
Whole blood viscosity (WBV) is increasingly recognized
as a factor implicated in the genesis of atherosclerosis
and the progression of vascular disease, such as chronic
kidney disease (CKD), in high-risk patients. The
principal determinants of WBV are hematocrit, red
blood cell deformability, and the viscosity of plasma.
Changes in whole blood viscoelasticity are associated
with cardiovascular and cerebrovascular complications
among patients with CKD, especially in the fifth stage
(1–3). Mechanical interaction between blood and
vessels mediated by WBV has a crucial role in the
release of endothelium-derived mediators such as NOx
and endothelin, and subsequent vascular remodeling
(1,4).
* Correspondence: meltemileri@yahoo.com
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The aim of the study was to investigate the effects of WBV
and plasma NOx values on cerebral and cardiovascular
risks associated with CKD and to compare the impact of
hemodialysis (HD) and peritoneal dialysis (PD) treatments
on WBV and plasma NOx levels in patients with CKD.
2. Materials and methods
A cross-sectional study was performed in patients who
were admitted to our pediatric nephrology department.
The study fulfilled the requirements of good clinical
practice according to the Declaration of Helsinki, and was
approved by our local ethics committee (Date: 13.04.2011,
Number: 66). Patients and their families were informed,
and all subjects gave written informed consent prior to
enrollment.
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The study group consisted of 40 patients aged 8–18
years (13.88 ± 3.02 years); the group included 20 patients
with stages III–IV CKD (predialysis patients: PreD), 10
on PD, 10 receiving HD, and 21 healthy control subjects
(12.90 ± 3.03 years). All were nonsmokers with no history
of recent blood transfusions or any medications likely
to affect blood viscosity. Control subjects were excluded
for any of the following: 1) congenital or coronary heart
disease; 2) diabetes mellitus; 3) hypertension; 4) kidney
disease; 5) taking fish oil supplements.
Ten stable HD patients (more than 6 months on
regular dialysis) were selected for the study from our
dialysis facility and from a training and research hospital;
this group consisted of 5 males and 5 females, with a mean
age of 15.10 ± 2.13 years and a dry weight of 36.50 ± 8.93
kg. The mean period of hemodialysis was 15.5 months (6–
48 months). The causes of CKD were neurogenic bladder
in 1, congenital anomalies of kidney and urinary tract
systems (CAKUT) in 1, Alport syndrome in 1, primary
hyperoxaluria in 1, nephrolithiasis in 1, vesicoureteral
reflux (VUR) in 2, and unknown etiology in 3 patients.
HD therapy was performed 3 times per week, with each
session lasting 240 minutes; 1.3–1.5 m2 filters were used,
depending on each patient’s weight and age. The effective
blood flow changed between 180 and 300 mL/min. Mean
weight loss equivalent to net ultrafiltration volume was
1.4 ± 0.5 kg. All patients were anuric. The prevention of
clotting of the extracorporeal circuit during treatment was
achieved using low-molecular–weight heparin injected
as a single intravenous bolus. Dosages were adjusted to
individual needs and did not change during the study.
Ten PD patients (more than 6 months on regular
dialysis) were selected for the study from our pediatric
nephrology department and from the other hospital, also
including 5 males and 5 females, with a mean age of 13.70
± 3.27 years and a dry weight of 28.70 ± 12.20 kg. The
mean period of peritoneal dialysis was 28.5 months (6–60
months). The causes of CKD were neurogenic bladder in
1, CAKUT in 1, nephronophthisis in 1, hemolytic uremic
syndrome in 1, nephrolithiasis in 1, VUR in 2, posterior
urethral valve in 1, and focal segmental glomerulosclerosis
in 2 patients. PD therapy was carried out as continuous
ambulatory peritoneal dialysis by the daily exchange
of dialysate fluid 4 times/day, 1100 mL/m². Four of the
peritoneal dialysis patients were anuric; for the others, the
urine output was 400 ± 50 mL/day.
Twenty preD patients were selected from our pediatric
nephrology department who were considered to have stage
III or IV CKD according to their creatinine clearance,
which was calculated according to the Schwartz formula
(5). CKD stage III is defined as a glomerular filtration rate
(GFR) between 30 and 59 mL/min/m², and stage IV is
defined as a GFR between 15 and 29 mL/min/m2, according

to the Schwartz formula (5). This group consisted of 14
males and 6 females, with a mean age of 13.35 ± 3.23 years
and a dry weight of 44.61 ± 17.01 kg. Etiologies of CKD
were VUR in 7, polycystic renal disease in 4, neurogenic
bladder in 3, nephronophthisis in 2, nephrolithiasis in 1,
posterior urethral valve in 1, CAKUT in 1, and unknown
in 2 patients.
The patient group was using supportive therapy set
up according to their needs, such as phosphate binders,
alkali therapy, and active vitamin D preparations. Blood
pressure of the patients was under control during the
evaluation. Seventeen patients (42.5%) were using
angiotensin-converting enzyme inhibitors in order to
regulate hypertension. Only 1 PD patient was using a lipidlowering drug. Erythropoietin stimulating agents had been
used in all HD patients, in 7 of the PD patients, and 3 of
the preD patients to correct anemia for 1 month to 6 years.
All patients were iron repleted. Iron supplementation was
given intravenously or orally according to the patients’
needs.
Venous blood samples were collected at a morning
clinic after overnight fasting, 24 h after the last session
in HD patients and early in the morning before dialysis
fluid instillation in PD patients. Hematologic findings and
biochemical variables were evaluated. WBV and plasma
NOx values were studied immediately on the same day of
the hematologic and biochemical evaluations.
Echocardiography was performed on the same
day as the examination of blood samples by the same
pediatric cardiologist, who was blind to the groups. All
echocardiographic examinations were performed by using
a Vivid 7 (GE Vingmed Ultrasound, Horten, Norway)
machine. Left ventricular functions were evaluated
according to the American Society of Echocardiography
Pediatric Guidelines (6). The left ventricular mass (LVM)
was calculated according to the formula by Devereux (7).
The left ventricular mass index (LVMI) was obtained by
dividing the LVM by height to the power of 2.7. Three
different models were used to determine left ventricular
hypertrophy (LVH) as defined by Khoury et al. (8): 1)
LVMI >38, 6 g/m2.7; 2) LVMI >51 g/m2.7; and 3) LVMI
>95th percentile for age and sex in normal children and
adolescents. LVMI >51 g/m2.7 indicated severe LVH in
patients.
Relative wall thickness (RWT) was calculated to
estimate the left ventricle (LV) geometric pattern using
the formula: Interventricular septum + LV posterior wall /
LV end diastolic diameter. The patients with LVMI >95%
and RWT >0.42 had concentric LVH; those with LVMI
>95% and RWT <0.42 had eccentric LVH. Concentric
remodeling was defined as LVMI is normal and RWT
>0.42 (9).
The left ventricular diastolic function was evaluated by
measuring mitral maximal early (E) and late (A) diastolic
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flow velocity ratio (E/A). Peak (E’) and atrial (A’) velocities
were measured by tissue Doppler using the sample volume
that was placed at the lateral annulus of the mitral valve.
To evaluate the late diastole, the mitral early inflow wave
(E) to lateral mitral annulus Doppler wave (E’) velocity
ratio was calculated (E/E’). An E/E’ ratio >10 represented
abnormal left ventricular diastolic functions, while an E/A
ratio of <1 or >3 was considered normal (10).
The middle cerebral artery blood flow velocity
(MCABFV) was examined by transcranial Doppler (TCD)
ultrasonography on the same day of the echocardiograpic
evaluation by the same neurologist, who was also blind
to the patients and groups. The middle cerebral arteries
were insonated through the temporal windows using
standardized protocol. Mean (Vm) velocities of the right
and left middle cerebral artery flow were recorded at
depths of 50–60 mm with a 2-MHz probe by the technique
described elsewhere by Aaslid (11). Only measurements
with the best signal-to-noise ratio were used and the highest
values for cerebral blood flow velocities were selected for
analysis. The sample volume was 8–10 mm in the axial and
5 mm in the lateral direction at a depth of 50 mm. All TCD
studies were performed by using a commercially available
Viasys/Sonara TCD apparatus (Cardinal Health, Madison,
WI, USA).
WBV measurement: The viscoelastic properties were
determined via measurement of the oscillatory flow in
a cylindrical tube called a Vilastic Bioprofiler (Vilastic
Scientific, Inc, Austin, TX, USA). For this measurement,
0.5 mL of the sample was used. Before the measurement,
the tube was filled with deionized water at 37 °C. When
the temperature equilibrium was established, the viscosity
of the deionized water was measured and substituted
with the sample’s viscosity. This was done to eliminate the
effect of the transport medium on the measurement of the
sample’s viscosity. All the measurements were taken under
constant temperature. To accomplish this, the device was
run under constant temperature for at least 40 min before
taking all the measurements. To eliminate the effect of the
time interval between gathering the sample and taking the
measurement, all the samples were evaluated in a constant
time of a maximum of 30 min after blood samples were
obtained. The results of viscosity were given as poise units
(12).
The NOx level measurement: the NOx level in whole
blood is determined by measuring nitrite and nitrate
production using classical colorimetric reaction. Plasma
samples for the determination of NOx concentration were
diluted 1:1(vol/vol) with 0.3 M NaOH and incubated for
5 min and then protein-precipitated using 10% ZnSO4.
The mixture was centrifuged for 10 min at 14,000 rpm.
Supernatants were collected and plated briefly; equal
volumes of samples and Griess reagent (sulfanilamide
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and naphthalene–ethylene diaminedihydrochloride) were
mixed at room temperature. After 5 min, the absorbance
was measured at 540 nm using a spectrophotometer. The
concentration of nitrite was determined by a standard
curve prepared with sodium nitrite (13).
2.1. Statistical analysis
Data analysis was performed using SPSS v.15.0 (Statistical
Package for the Social Sciences, Chicago, IL, USA).
Continuous variables were presented as a mean and
standard deviation (SD) or median and interquartile
range (IQR), and categorical variables were presented as
frequency and percentages. Continuous variables were
compared using one-way ANOVA with a Tukey posthoc test or a Kruskal–Wallis H test with a Bonferroniadjusted Mann–Whitney U test, depending on normality
of distribution or not. Bivariate correlation coefficients
were calculated using the Pearson product moment
or Spearman’s rank test, depending on normality of
distribution or not. All statistical analyses were two-sided,
and a P-value <0.05 was considered to be statistically
significant.
3. Results
Demographic findings and the main clinical and biological
characteristics of all patients and controls are given in
Table 1. Laboratory results, plasma NOx, and MCABV
values for all study groups can be seen in Table 2.
The mean WBV was higher in the control subjects
than in the patient groups, while there was no significant
difference between the WBV values in all patients.
Plasma hematocrit, total protein, and albumin levels
were lower in all patient groups than those in the control
patients. On the other hand, ferritin levels in the PreD,
HD, and PD groups were higher than those in the control
group. Additionally, homocysteine levels were higher in the
PD and PreD groups than in the HD patients and healthy
controls. There was a significant positive correlation
between WBV and hematocrit and serum albumin levels
in the study group (P < 0.05) (Figure). There was a positive
correlation between WBV and fibrinogen levels and a
negative correlation between WBV and homocysteine
levels in the study group, but neither was significant (P >
0.05). A significant positive correlation was found between
plasma NOx levels and ferritin in the patient group (P <
0.05).
Plasma NOx levels were higher in HD/PD patients
than those in the PreD group, but plasma NOx levels were
lower in the control group than those in all patient groups.
An insignificant negative correlation was found
between WBV and plasma NOx levels (P > 0.05).
For echocardiographic evaluation, the left ventricular
systolic functions were not different between the groups.
LVMI was significantly higher in all patient groups than in
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Table 1. Demographic findings and the main clinical and biological characteristics of all patients and controls.
HD
(N = 10)

Variables

PD
(N = 10)

PreD
(N = 20)

Control
(N = 21)

Age (year)

15.10

± 2.13

13.70

± 3.27

13.35

± 3.23

12.90

± 3.03

Weight (kg)

36.50

± 8.93

28.70

± 12.20 a

44.61

± 17.01

45.48

± 13.56

Height (cm)

144.40

± 14.06

131.60

± 22.01 a

149.30

± 19.73

152.90

± 17.90

BMI (kg/m )

17.29

± 1.81

15.87

± 2.83 a

19.22

± 3.39

18.98

± 2.56

2

SBP (mmHg)

109.00

± 20.25

103.50

± 21.35

102.00

± 15.76

98.57

± 13.52

DBP (mmHg)

70.00

± 14.14

67.50

± 13.18

65.50

± 11.46

63.81

± 11.61

HD: hemodialysis, PD: peritoneal dialysis, PreD: predialysis, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood
pressure.
a
P < 0.05 versus PreD and control.
Table 2. Laboratory results and MCABV values in all study groups.
Variables

HD
(n: 10)

PD
(n: 10)

PreD
(n: 20)

Control
(n: 21)

Red blood cell (×104/mm3)

3.42 ± 0.59

3.29 ± 0.78

4.01 ± 0.83

4.96 ± 0.47 a

Hematocrit (%)

30.22 ± 5.89

29.41 ± 7.17

33.25 ± 6.61

41.40 ± 3.67 a

Hemoglobin (g/dL)

10.06 ± 1.90

10.02 ± 2.44

11.11 ± 2.26

14.11 ± 1.15 a

Albumin (g/dL)

4.12 ± 0.53

3.69 ± 0.41

4.35 ± 0.34 b

4.79 ± 0.28 a

Total protein (g/dL)

7.01 ± 0.84

6.34 ± 0.57

7.26 ± 0.60

7.65 ± 0.37 a

Ferritin (ng/mL)

293.0 (265.5–345.0)

220.7 (137.9–347.8)

40.1 (24.8–125.0) c

17.0 (14.8–28.3) a

Lipoprotein A (mg/dL)

29.3 (9.7–36.3)

27.9 (11.5–46.1)

17.2 (9.5–34.5)

17.7 (9.5–34.5)

Fibrinogen (mg/dL)

363.0 (300.0–434.0)

398.5 (358–487)

350.5 (296.0–396.0)

260.0 (248–287) a

hsCRP (mg/dL)

0.44 (0.05–1.42)

0.08 (0.03–0.20)

0.16 (0.05–0.64)

0.03 (0.02–0.10) d

Homocysteine (µmol/L)

15.9 (13.7–28.9)

22.3 (16.9–23.7) e

21.3 (17.5–30.6) e

14.5 (12.0–18.2)

LDL(mg/dL)

76.7 (51.0–116.4)

109.0 (102.0–136.8)

89.3 (71.2–102.4) b

83.0 (73.6–90.0) b

HDL(mg/dL)

36.5 (33.0–40.0)

42.0 (37–48)

42.5 (40.0–48.5)

51.0 (41–60) a

Triglyceride(mg/dL)

184.9 ± 97.2

170.9 ± 58.9

127.8 ± 50.9

77.0 ± 21.0 a

Whole blood viscosity (spoise)

0.0387 ± 0.011

0.0418 ± 0.013

0.0423 ± 0.013

0.0601 ± 0.006 a

MCABFV (cm/s)

62.26 ± 12.36

70.84 ± 15.92

65.86 ± 14.79

68.24 ± 11.09

Plasma NOx (nmol/mL)

119.18 ± 20.61

115.77 ± 15.11

78.41 ± 11.24

66.03 ± 14.34a

b

c

Data are presented as mean ± standard deviation or median (IQR).
HD: hemodialysis, hsCRP: high sensitive C-reactive protein; PD: peritoneal dialysis, PreD: predialysis, HDL: High density lipoprotein
cholesterol, LDL: low density lipoprotein cholesterol, MCABFV: middle cerebral artery blood flow velocity, plasma NOx: plasma nitric
oxide.
a
P < 0.05 versus HD, PD, and PreD. b P < 0.05 versus PD. c P < 0.05 versus HD and PD.
d
P < 0.05 versus HD and PreD. e P < 0.05 versus HD and control.

the healthy subjects. While the E/A ratio was significantly
different between both the HD and PreD groups and the
controls, the E’/A’ ratio value was significantly lower in all
patient groups than in the control group (P < 0.05). The
E/E’ ratio value for all patient groups was also different
significantly from that of the controls (P < 0.05).

LVH presentation was similar in patients for both
LVMI > 38.6 g/m2.7 model and LVMI > 95% model (Table
3). According to these 2 models, LVH was present in twothirds of all patients. While concentric hypertrophy was
present in 42.5% of all patients, eccentric hypertrophy was
found in 17.5% of all patients. The concentric hypertrophy
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Figure. Correlations of whole blood viscosity and albumin and hematocrit levels in the patient and control groups.

most presented LV geometry in HD and PD groups (Table
4).
Although there was no significant correlation between
echocardiographic parameters and plasma NOx values,
WBV correlated positively significant in controls with
LVMI (P < 0.05). In the patient group, there was a negative
correlation between WBV and LVMI, but it was not
significant (P > 0.05).
For transcranial Doppler ultrasonography examination,
when the MCABFV values were examined, no statistically
significant difference was present in MCABFV between
the patient and control groups (Table 2). In addition,
a negative correlation was found between WBV and
MCABFV values in the studied patient subgroups and the
controls, but it was not significant (P > 0.05). There was
no significant correlation between plasma NOx values and
MCABFV in the study group (P > 0.05).
4. Discussion
Chronic inflammation, increased oxidative stress,
proteinuria, hypoalbuminemia, hypertension, renin–
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angiotensin–aldosteron system activation, dyslipidemia,
altered calcium–phosphate metabolism, chronic acidosis,
and anemia are the most important risk factors for the
progression of CKD. Preventive measures should be
taken to slow down the rate of CKD progression and to
delay the need for renal replacement therapy, including
transplantation and receiving HD or PD therapy. Children
with CKD are at high risk of developing cardiovascular
disease and cerebrovascular events (14). WBV depends
on the blood composition, including blood cells
(erythrocytes, leukocytes) and plasma proteins (albumin,
globulins, and fibrinogen) in humans. Hemoglobin
and fibrinogen were shown as the 2 major contributory
factors that affect WBV (4). However, in CKD patients,
data about WBV is confusing and controversial (14–
19). Hypoalbuminemia associated with CKD has been
shown to cause hyperviscosity by enhancing a reduction
in erythrocyte deformability. Additionally, an albumin
deficiency increases fibrinogen and triglyceride levels
and may alter red cell membrane lipid composition
(16,17). Furthermore, elevated homocysteine levels in
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Table 3. Echocardiographic measurements of patients and control group.
Variables

HD
(N = 10)

PD
(N = 10)

PreD
(N = 20)

Control
(N = 21)

EF (%)

73.46 ±13.81

75.19 ± 6.22

73.07 ± 5.35

71.13 ± 5.30

FS (%)

43.56 ± 13.03

43.66 ± 5.68

43.05 ± 5.78

39.95 ± 4.17

LVMI (g/m2)

66.94 ± 29.59

50.94 ± 15.09

40.47 ± 10.94

31.76 ± 7.95 a

E / A ratio

1.47 ± 0.17

1.42 ± 0.46

1.49 ± 0.26

1.73 ± 0.30 b

E’ / A’ ratio

1.80 ± 0.65

1.74 ± 0.79

2.14 ± 0.71

2.69 ± 0.78 a

E / E’ ratio

13.13 ± 5.86

9.82 ± 2.77

8.64 ± 2.59

6.29 ± 2.80 a

HD: hemodialysis, PD: peritoneal dialysis, PreD: predialysis, EF: ejection fraction, FS: fractional
shortening, LVMI: left ventricle mass index, E: mitral diastolic early inflow velocity wave, E’: early
diastolic mitral annulus velocity wave, A: mitral diastolic late inflow velocity wave, A’: late diastolic
mitral annulus velocity wave, E/A ratio: ratio of mitral early to late inflow velocity, E’/A’: ratio of early
diastolic mitral annulus velocity to late diastolic mitral annulus velocity, E/E’: ratio of early transmitral
inflow velocity divided by the early diastolic mitral annular velocity.
a
P < 0.05 versus HD, PD, and PreD.
b
P < 0.05 versus HD and PreD.

Table 4. Different definitions of left ventricular hypertrophy models.
Variables

HD

PD

PreD

8 (28.6)

8 (28.6)

10 (35.7)

LVMI > 51 g/m2.7

5 (38.5)

5 (38.5)

2 (15.4)

LVMI > 95%

7 (28.0)

7 (28.0)

10 (40.0)

LVMI > 38.6 g/m

2.7

Concentric hypertrophy

7 (38.9)

6 (33.3)

4 (22.2)

Concentric remodeling

1 (5.3)

-

5 (26.3)

Eccentric hypertrophy

-

1 (14.3)

6 (85.7)

Data are presented as number of patients and percentages.
HD: hemodialysis, PD: peritoneal dialysis, preD: predialysis, LVMI: left ventricle
mass index.

addition to hypoalbuminemia and hyperfibrinogemia are
considered to be other factors that contribute to the risk of
atherosclerosis in CKD patients. As a result, these changes
increase the risk of thrombosis by increasing plasma
viscosity and red blood cell and platelet aggregation and by
promoting fibrin deposition plaques, and may contribute
to hypertension by increasing peripheral resistance (18).
In this study, the systolic blood pressure and diastolic
blood pressure of all patients were kept under control
by the use of antihypertensive monotherapy. All of the
patients were normotensive at the time of investigation.
According to our laboratory results, serum albumin levels
were significantly lower in all patient subgroups than in
healthy subjects. The significantly lower values of albumin
may be due to the malnutrition of all subjects in the

patient group. Protein loss from peritoneal membrane in
PD patients might be another reason. Moreover, serum
fibrinogen levels were significantly higher in all patients
than in the controls. These results could be explained
not only by the increasing fibrinogen values resulting
from an albumin deficiency but also by accompanying
systemic inflammation in CKD patients. Additionally,
homocysteine levels were found to be higher in the PD and
PreD groups than in the HD patients and healthy controls.
No significant correlation was found in our study; however,
some studies have shown that plasma homocysteine and
fibrinogen levels were correlated with plasma viscosity
(19). In the present study, there was a positive correlation
between WBV and fibrinogen levels and a negative
correlation between WBV and homocysteine levels in the
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study group; it might be expected that the relationship
might be stronger and more significant with an increased
number of patients. Finally, the WBV values of all of the
patients were significantly lower than the control group.
It can be concluded that significantly lower values of
hematocrit, total protein, and albumin and higher values
of ferritin in all patient groups might result in low WBV
levels in patients with CKD.
It is worth noting that cardiovascular complications
have accounted for 21% to 57% of deaths among children
receiving HD (20,21). In HD patients, the role of rapid fluid
volume removal has generally been ignored (22). FathallahShaykh et al. demonstrated that WBC increased linearly
over HD sessions in both children and adults. A significant
correlation between increased WBV and hematocrit, the
amount of ultrafiltration volume, and a decline in blood
volume was shown in the same study as well (21). In our
study, venous blood samples were collected 24 h after the
last session in HD patients and early in the morning before
dialysis fluid instillation in PD patients. Because WBV was
evaluated in an interdialytic period, our laboratory results
are not expected to be affected by the acute rise in WBV
after the HD sessions.
In brief, the following conclusions can be drawn in
each part of the study, as for the NOx examination; NOx
is an important substance in the maintenance of vascular
tone and regulation of blood pressure. Physiological
and pathophysiological mechanisms of CKD can cause
damage of endothelium or blood vessels. It was shown
that the disturbances of vasoactive substances like NOx
production can result in significant hemodynamic
problems and atherosclerosis in patients with CKD (23).
The plasma concentration and urinary excretion of NO2
and NO3 (NOx; the stable oxidation products of NO)
are now being widely used to give a measure of total NO
production in vivo (24,25). In the literature, the results of
the studies that investigated the plasma levels and effects
of NOx in patients with CKD were controversial. Some
studies have supported that plasma NOx levels were lower
in CKD patients (23,26–27). Total NO production was in
a small number of patients with chronic renal failure, but
the patient group was reported to be hypertensive during
the investigation (28). On the other hand, the results of
some studies on the plasma NOx levels of dialysis patients
supported the high plasma NOx values resulting from a
complete loss of renal clearance and the removal of NO
inhibitors such as asymmetric dimethylarginine (ADMA)
by dialysis (15,23,28–30). Recent data also supported
our finding that higher degree of inflammation and
stimulation of the inducible form of nitric oxide synthase
results in higher values of NOx in CKD patients (31,32).
These literature findings supported our results showing
higher plasma NOx levels in HD/PD patients than those in
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the preD group, but lower NOx levels in the control group
than those in all patient groups. Our data also showed that
the blood pressure of all of our patients was under control
with antihypertensive therapy. The reason is not clear, but
most likely a high level of NOx as a potent vasodilator
might have an additional effect on the restoration of blood
vessel tension down to normal.
In terms of our echocardiographic examination, there
have been many studies assessing the left ventricular
diastolic functions in children with renal failure. The most
widely used method to determine the diastolic functions
of LV is Doppler examination of the mitral inflow velocity.
These studies have shown that the LV relaxation (E/A)
was impaired in children under dialysis (22,33–35). Our
Doppler findings were supported by the literature findings.
We found a lower E/A ratio in patients compared to the
controls, although none of these patients had an E/A value
<1, which is considered to be abnormal (36). On the other
hand, transmitral Doppler velocities are affected by several
hemodynamic factors that are particularly important for
patients with chronic renal failure. Therefore, we studied
tissue Doppler imaging in our study group as suggested by
the literature (9). The E/E’ ratio is especially suggested for
the evaluation of LV filling pressures and LV myocardial
compliance in patients with preserved systolic functions,
especially as an early predictor of diastolic heart failure
(9,36). High values of E/E’ ratios were significantly
associated with the high incidence of mortality in chronic
renal failure patients in adults, especially ratios >15 (37). In
our study, patients were evaluated echocardiographically
within 24 h of completing their dialysis treatment to
minimize the effect of fluid overload. We found that the
E/E’ ratio values of all subgroups were significantly higher
than those of the controls. An E/E’ ratio >10 represented
abnormal left ventricular diastolic functions; the patient
group, especially the HD patients, had the highest E/E’
ratio, suggesting diastolic dysfunction. A statistically
significant correlation between an elevated LVMI value
and an increased E/E’ ratio was found in all patients.
According to these findings, it can be concluded that
while the patients had normal systolic functions, their
LV myocardial compliance and filling pressures were still
impaired, suggesting the deterioration of diastolic function.
LVH is defined as the most important independent
marker of cardiovascular risks and is the most common
and identifiable cardiac alteration in patients with chronic
renal insufficiency (38). Concentric hypertrophy was the
most often presented LV geometry in HD and PD groups
in our study, concordant with the literature (39). Increased
LVMI might have been caused by previous hypertension,
especially in the patients having concentric hypertrophy
during the study. Additionally, the undetermined volume
load may have an alternative explanation for increased
LVMI apart from a history of hypertension, which was
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under control during the study. The high prevalence
of volume-dependent eccentric LVH, especially in
predialysis patients, suggests that fluid overload rather
than hypertension is likely a cause of LVH.
In terms of TCD ultrasound, it has been stated that
under normal conditions, a 3-fold variation in plasma
viscosity with a 2-fold variation in whole blood viscosity
did not significantly alter cerebral blood flow (40).
Although there have been some data supporting the
relationship between hyperviscosity and cerebrovascular
events in CKD patients in adults, there are no available
data in children (41–43). No statistically significant
difference was present in MCABFV between patients and
control groups in our study. We think cerebral circulation
has the ability to make adaptive modulations in terms of
changes in viscosity, in order to keep up uniform cerebral
blood flow. In addition, a negative correlation was found
between WBV and MCABFV values in the studied patient
subgroups and the controls, but it was not significant. It
is expected that studies having large number of patients
might emphasize the relationship between WBV and
MCABFV in children. No other studies have evaluated the
relation between viscosity, plasma NOx, and MCABFV in
children with CKD in the literature.
In conclusion, although there have been some data
supporting the relationship between hyperviscosity,
plasma NOx, and cerebrovascular as well as cardiovascular
events in CKD patients, no significant correlations were

found among those parameters in this study. However,
our results showed that a negative correlation was found
between WBV and MCABFV values in the studied group.
WBV was significantly associated with lower hemoglobin,
hematocrit, and albumin levels and higher levels of
ferritin. Plasma NOx levels were higher in CKD patients,
suggesting the complete loss of renal clearance and the
removal of NO inhibitors such as ADMA by dialysis and
stimulation of the inducible form of nitric oxide synthase
through a higher degree of inflammation in CKD patients.
Increased plasma NOx levels in the patient group might be
associated with blood pressure maintained within normal
ranges. Increased levels of plasma NOx levels in the patient
group might have an additional effect on keeping blood
pressure within normal range under antihypertensive
monotherapy. Higher levels of LVMI indicated the prior
hypertensive state of the patients. Even systolic functions
in the normal patient group had significant deterioration
in diastolic functions, suggesting their morbidity and
mortality risks. Concentric LVH was predominant in the
patient group. The metabolism of NOx levels needs further
investigation with a large number of patients with chronic
renal disease to illuminate this issue.
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